-
-
METHYLPREDNISOLONE (Generic for MEDROL)
- QTY 21
- 4 MG
- TAB DS PK
- Near 77381
METHYLPREDNISOLONE (meth ill pred NISS oh lone) treats many conditions such as asthma, allergic reactions, arthritis, inflammatory bowel diseases, adrenal, and blood or bone marrow disorders. It works by decreasing inflammation, slowing down an overactive immune system, or replacing cortisol normally made in the body. Cortisol is a hormone that plays an important role in how the body responds to stress, illness, and injury. It belongs to a group of medications called steroids.
Change Location
Set Price Drop Alert for:
METHYLPREDNISOLONE (Generic for MEDROL)
- QTY 21
- 4 MG
- TAB DS PK
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
METHYLPREDNISOLONE (Generic for MEDROL)
- QTY 21
- 4 MG
- TAB DS PK
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Pill Splitting
Change Form
Medicine Chest
METHYLPREDNISOLONE (Generic for MEDROL) Lifestyle Interactions
-
Tofacitinib 5mg, Oral tablet
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: It is best to avoid taking Tofacitinib with grapefruit juice and to avoid grapefruit juice completely during your Tofacitinib treatment. Grapefruit juice may increase the levels of Tofacitinib and the risk for side effects from your treatment. Talk to your health care professional or pharmacist for recommendations.• Notes for Professionals: It is best to avoid taking Tofacitinib with grapefruit juice. The exposure to tofacitinib may be significantly increased in patients who regularly consume grapefruit or grapefruit juice, a strong CYP3A4 inhibitor. FDA-approved labeling recommends in patients receiving 5 mg or less twice daily, reduce to once daily dosing; in patients receiving 10 mg twice daily, reduce to 5 mg twice daily; in patients receiving 22 mg once daily of the extended-release (XR) formulation, switch to 11 mg XR once daily; in patients receiving 11 mg XR once daily, switch to the immediate-release formulation at a dose of 5 mg once daily. No specific guidance is provided for grapefruit or grapefruit juice. Coadministration with another strong CYP3A4 inhibitor increased tofacitinib exposure by 2-fold.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
